Osiris Rises On Unusually High Volume (OSIR)

NEW YORK ( TheStreet) -- Osiris Therapeutics (Nasdaq: OSIR) is trading at unusually high volume Friday with 1.1 million shares changing hands. It is currently at 4.2 times its average daily volume and trading up 56 cents (+4.8%) at $12.15 as of 2 p.m. ET.

Osiris has a market cap of $364 million and is part of the health care sector and drugs industry. Shares are up 107.1% year to date as of the close of trading on Thursday.

Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, cardiovascular, orthopedic, and wound healing markets. It operates in two segments, Therapeutics and Biosurgery. The company has a P/E ratio of 38.2, below the average drugs industry P/E ratio of 39.6 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Osiris as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. You can view the full Osiris Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing